β‐Glucuronidase‐Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool

β‐Glucuronidase‐Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool

Abstract Irinotecan (CPT11)‐induced diarrhea affects 80–90% of cancer patients due to β‐glucuronidase (GUS) converting 7‐ethyl‐10‐hydroxycamptothecin glucuronide (SN38G) to 7‐ethyl‐10‐hydroxycamptothecin (SN38). It remains unclear whether SN38 impacts the homeostasis between gut microbiota and mucos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bei Yue, Ruiyang Gao, Ling Zhao, Donghui Liu, Cheng Lv, Ziyi Wang, Fangbin Ai, Beibei Zhang, Zhilun Yu, Xiaolong Geng, Hao Wang, Kang Wang, Kaixian Chen, Chenghai Liu, Zhengtao Wang, Wei Dou
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	Advanced Science
Subjects:	epithelial regeneration irinotecan‐induced intestinal toxicity GUS‐expressing bacteria lactobacillus reuteri Xianglian pill
Online Access:	https://doi.org/10.1002/advs.202411052
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeted inhibition of Gus-expressing Enterococcus faecalis to promote intestinal stem cell and epithelial renovation contributes to the relief of irinotecan chemotoxicity by dehydrodiisoeugenol
by: Ruiyang Gao, et al.
Published: (2024-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Development and Characterization of Optimized Drug-Loaded Niosomes for Delivery of 5-FU and Irinotecan
by: Kafilat O. Agbaje, et al.
Published: (2025-07-01)

Biochemical and functional properties of vesicles from planktonic and biofilm phenotypes of Limosilactobacillus reuteri DSM 17938
by: Beatrice Marinacci, et al.
Published: (2025-05-01)

Development of pilot technology for liposomal irinotecan production
by: O. V. Stadnichenko, et al.
Published: (2018-08-01)

The effects of cell-free extracts derived from probiotic strains Bifidobacterium bifidum and Lactobacillus reuteri on the proliferation and biofilm formation by Lactobacillus reuteri in vitro
by: O. V. Knysh
Published: (2019-12-01)

Experimental Study of Irinotecan Induced Side Effects on Digestive and Immune System of Mice
by: Liya LIU, et al.
Published: (2018-04-01)

Heterologous Expression and Enzymatic Properties of β-Glucuronidase from <i>Clostridium perfringens</i> and Its Application in Bilirubin Transformation
by: Qianlin Wu, et al.
Published: (2025-04-01)

Transfer of a β-Glucuronidase Marker Gene to Triticale (xTriticosecale Wittmack) via Particle Bombardment (Biolistic) Method*
by: Melahat Avcı Birsin
Published: (2013-05-01)

Influence of lipid concentration on encapsulation and particle size in the development of liposomal irinotecan
by: A. V. Stadnichenko, et al.
Published: (2017-04-01)

Limosilactobacillus reuteri prevents progression of ankylosing spondylitis in mice by restoring gut microbiota-metabolism homeostasis
by: Lianjun Yang, et al.
Published: (2025-07-01)

Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA
by: Yongcheng Jiang, et al.
Published: (2025-06-01)

The effects of Lactobacillus reuteri on the inflammation and periodontal tissue repair in rats: A pilot study
by: Valdir Gouveia Garcia, et al.
Published: (2022-09-01)

Current Updates on <i>Limosilactobacillus reuteri</i>: Brief History, Health Benefits, Antimicrobial Properties, and Challenging Applications in Dairy Products
by: Emília Maria França Lima, et al.
Published: (2025-02-01)

Oral probiotic supplementation to alleviate diarrhea induced by fluoropyrimidines or irinotecan-based chemotherapy: A systematic review and meta-analysis
by: Tippawan Siritientong, et al.
Published: (2025-05-01)

Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis
by: Chengyi Huang, et al.
Published: (2025-03-01)

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany
by: S. Lonardi, et al.
Published: (2025-09-01)

Modulation of gut microbiota and immune response by soy peptides mitigates irinotecan induced intestinal toxicity
by: Yongfa Jing, et al.
Published: (2025-06-01)

Protective effects of N-acetylcysteine against irinotecan – induced pulmonary toxicity in female albino rats
by: Hawrin Burhan Khudhur, et al.
Published: (2024-12-01)

Therapeutic Effect of Brucea Javanica Oil Emulsion in Mice with Irinotecan-Induced Delayed Diarrhea
by: Lai Z, et al.
Published: (2025-06-01)

Limosilactobacillus reuteri - a probiotic gut commensal with contextual impact on immunity
by: Amanda H. Lee, et al.
Published: (2025-12-01)

Lactobacillus reuteri cell-free extracts against antibiotic-resistant bacteria
by: O. V. Knysh, et al.
Published: (2020-08-01)

The probiotic characteristics of Lactobacillus reuteri ZJ617 and its resistance to Escherichia coli O157:H7 challenge in HFD-fed mice
by: Yanfei Ma, et al.
Published: (2025-01-01)

Biological Characteristics Analysis of Limosilactobacillus reuteri JBR3 and the Effect of Protective Agents on Its Viability
by: Jun HAN, et al.
Published: (2025-02-01)

The Role of Lactobacillus reuteri DSMZ17648 for Helicobacter pylori eradication therapy (Review of literature and advisory council resolution, February 28, 2018)
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
by: T. Shirakawa, et al.
Published: (2025-06-01)

Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment
by: Xiaoqin Yang, et al.
Published: (2025-03-01)

The potential of reuterin derived from Indonesian strain of Lactobacillus reuteri against endodontic pathogen biofilms in vitro and ex vivo
by: Armelia Sari Widyarman, et al.
Published: (2023-02-01)

Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial
by: Chao Deng, et al.
Published: (2024-11-01)

The Role of Lactobacillus reuteri DSM 17938 in Athletic Performance and Recovery
by: Julia Charkot, et al.
Published: (2025-07-01)

Lactobacillus reuteri DSM 17,938 ameliorates LPS-induced depression-like and anxiety-like behaviors by modulating gut microbiota and brain metabolic function
by: Xiaolong Mo, et al.
Published: (2025-08-01)

Regulation of histidine metabolism by Lactobacillus Reuteri mediates the pathogenesis and treatment of ischemic stroke
by: Kangrui Hu, et al.
Published: (2025-01-01)

Effects of dietary sodium alginate and Lactobacillus reuteri on the growth, antioxidant capacity and intestinal health of largemouth bass (Micropterus salmoides)
by: Qing Kong, et al.
Published: (2025-07-01)

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024
by: Siyu Lou, et al.
Published: (2025-06-01)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
by: Koji Kikuchi, et al.
Published: (2022-10-01)

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
by: Zuojuan Xiang, et al.
Published: (2024-12-01)

Effect of Lactobacillus reuteri probiotic on gingival index and Interleukin-1β levels of children with thalassemia experiencing gingivitis
by: Indira Betari Sumendap, et al.
Published: (2025-04-01)

Reutericyclin, a specialized metabolite of Limosilactobacillus reuteri, mitigates risperidone-induced weight gain in mice
by: Fatima A. Aboulalazm, et al.
Published: (2025-12-01)

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients
by: Shuai Geng, et al.
Published: (2025-03-01)

Dietary Qiwenghuangbo powder–enriched Limosilactobacillus reuteri protects the intestinal epithelium and alleviates inflammation via a strain‐specific mechanism
by: Qian Xu, et al.
Published: (2025-06-01)